4.8 Article

PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma

Journal

ONCOGENE
Volume 38, Issue 25, Pages 5021-5037

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41388-019-0773-y

Keywords

-

Funding

  1. IDIBELL Fellowship
  2. Spanish Ministry of Science and Innovation Fellowships
  3. Spanish Ministry of Economy and Competitiveness MINECO [SAF2014-55944R, SAF2017-84976R]
  4. FEDER funds/European Regional Development Fund (ERDF)
  5. Catalan Department of Health (Generalitat de Catalunya) [2017SGR595]

Ask authors/readers for more resources

Advanced and undifferentiated skin squamous cell carcinomas (SCCs) exhibit aggressive growth and enhanced metastasis capability, which is associated in mice with an expansion of the cancer stem-like cell (CSC) population and with changes in the regulatory mechanisms that control the proliferation and invasion of these cells. Indeed, autocrine activation of PDGFR alpha induces CSC invasion and promotes distant metastasis in advanced SCCs. However, the mechanisms involved in this process were unclear. Here, we show that CSCs of mouse advanced SCCs (L-CSCs) express CXCR4 and CXCR7, both receptors of SDF-1. PDGFR alpha signaling induces SDF-1 expression and secretion, and the autocrine activation of this pathway in L-CSCs. Autocrine SDF-1/CXCR4 signaling induces L-CSC proliferation and survival, and mediates PDGFR alpha-induced invasion, promoting in vivo lung metastasis. Validation of these findings in patient samples of skin SCCs shows a strong correlation between the expression of SDF1, PDGFRA, and PDGFRB, which is upregulated, along CXCR4 in tumor cells of advanced SCCs. Furthermore, PDGFR regulates SDF-1 expression and inhibition of SDF-1/CXCR4 and PDGFR pathways blocks distant metastasis of human PD/S-SCCs. Our results indicate that functional crosstalk between PDGFR/ SDF-1 signaling regulates tumor cell invasion and metastasis in human and mouse advanced SCCs, and suggest that CXCR4 and/or PDGFR inhibitors could be used to block metastasis of these aggressive tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Jorge Gomez-Miragaya, Ander Diaz-Navarro, Raul Tonda, Sergi Beltran, Luis Palomero, Marta Palafox, Lacey E. Dobrolecki, Chen Huang, Suhas Vasaikar, Bing Zhang, Gerburg M. Wulf, Alejandro Collado-Sole, Eva M. Trinidad, Purificacion Munoz, Laia Pare, Aleix Prat, Alejandra Bruna, Carlos Caldas, Joaquin Arribas, Maria Teresa Soler-Monso, Anna Petit, Judith Balmana, Cristina Cruz, Violeta Serra, Miguel Angel Pujana, Michael T. Lewis, Xose S. Puente, Eva Gonzalez-Suarez

CANCER RESEARCH (2019)

Review Oncology

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

Roger von Moos, Luis Costa, Eva Gonzalez-Suarez, Evangelos Terpos, Daniela Niepel, Jean-Jacques Body

CANCER TREATMENT REVIEWS (2019)

Article Biochemistry & Molecular Biology

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

Laia Pique, Alexia Martinez de Paz, David Pineyro, Anna Martinez-Cardus, Manuel Castro de Moura, Pere Llinas-Arias, Fernando Setien, Jorge Gomez-Miragaya, Eva Gonzalez-Suarez, Stefan Sigurdsson, Jon G. Jonasson, Alberto Villanueva, August Vidal, Veronica Davalos, Manel Esteller

ONCOGENE (2019)

Article Cell Biology

PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1

Adriana Iriarte, Agnes Figueras, Pau Cerda, Jose Maria Mora, Anna Jucgla, Rosa Penin, Francesc Vinals, Antoni Riera-Mestre

CELLS (2019)

Article Biochemistry & Molecular Biology

SGK1 is a signalling hub that controls protein synthesis and proliferation in endothelial cells

Ferran Medina-Jover, Nuria Gendrau-Sanclemente, Francesc Vinals

FEBS LETTERS (2020)

Article Oncology

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

Adria Bernat-Peguera, Juan Navarro-Ventura, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luis Palomero, Rosa M. Penin, Diana Perez Sidelnikova, Josep Oriol Bermejo, Miren Taberna, Noelia Vilarino, Josep M. Piulats, Ricard Mesia, Joan Maria Vinals, Eva Gonzalez-Suarez, Salvador Capella-Gutierrez, Alberto Villanueva, Francesc Vinals, Purificacion Munoz

Summary: EGFR-targeted therapy may be effective for treating cSCCs conserving epithelial traits, but resistance may occur in tumors with the E545K PIK3CA-activating mutation. Some initially responding tumors develop resistance after long-term treatment, induced by bypassing from EGFR signaling to FGFR signaling. Pharmacologic inhibition of FGFR signaling can overcome resistance to EGFR inhibitors.

CLINICAL CANCER RESEARCH (2021)

Article Genetics & Heredity

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W. Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H. Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Vito W. Rebecca, Hua Sun, R. Jay Mashl, Sherri R. Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C. O'Farrell, Elodie Modave, Diether Lambrechts, Petra ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A. Dean, Brandi Davis-Dusenbery, Yvonne A. Evrard, James H. Doroshow, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Bingliang Fang, Jack A. Roth, Funda Meric-Bernstam, Meenhard Herlyn, Michael A. Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A. Moscow, Livio Trusolino, Annette T. Byrne, Jos Jonkers, Carol J. Bult, Enzo Medico, Jeffrey H. Chuang

Summary: The analysis of copy number alterations in patient-derived xenografts (PDXs) and matched patient tumor samples reveals strong conservation of copy number alterations from patient tumors through late-passage PDXs, without systematic evolution driven by the mouse host. This suggests that PDX models are accurate in representing human cancer and that the mouse host does not significantly impact the copy number alterations during tumor evolution within the PDX model.

NATURE GENETICS (2021)

Article Multidisciplinary Sciences

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+T cells

Clara Gomez-Aleza, Bastien Nguyen, Guillermo Yoldi, Marina Ciscar, Alexandra Barranco, Enrique Hernandez-Jimenez, Marion Maetens, Roberto Salgado, Maria Zafeiroglou, Pasquale Pellegrini, David Venet, Soizic Garaud, Eva M. Trinidad, Sandra Benitez, Peter Vuylsteke, Laura Polastro, Hans Wildiers, Philippe Simon, Geoffrey Lindeman, Denis Larsimont, Gert Van den Eynden, Chloe Velghe, Francoise Rothe, Karen Willard-Gallo, Stefan Michiels, Purificacion Munoz, Thierry Walzer, Lourdes Planelles, Josef Penninger, Hatem A. Azim, Sherene Loi, Martine Piccart, Christos Sotiriou, Eva Gonzalez-Suarez

NATURE COMMUNICATIONS (2020)

Article Cell Biology

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

Sandra Benitez, Alex Cordero, Patricia G. Santamaria, Jaime Redondo-Pedraza, Ana S. Rocha, Alejandro Collado-Sole, Maria Jimenez, Adrian Sanz-Moreno, Guillermo Yoldi, Juliana C. Santos, Ilaria De Benedictis, Clara Gomez-Aleza, Sabela Da Silva-Alvarez, Kevin Troule, Gonzalo Gomez-Lopez, Noelia Alcazar, Ignacio Palmero, Manuel Collado, Manuel Serrano, Eva Gonzalez-Suarez

Summary: Rank signaling enhances stemness and delays tumor initiation by inducing senescence in mammary epithelial cells, yet eventually promotes tumor progression and metastasis.

DEVELOPMENTAL CELL (2021)

Article Oncology

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data

Adria Bernat-Peguera, Macedonia Trigueros, Angelica Ferrando-Diez, Cristina Ibanez, Sara Bystrup, Anna Martinez-Cardus, Mireia Margeli, Eva Martinez-Balibrea

Summary: The study shows that the combination of CT-P6 and pertuzumab with chemotherapy is equivalent to reference trastuzumab (RTZ) in treating early breast cancer patients, with no differences in efficacy or adverse events. Additionally, the use of CT-P6-based treatments reduces costs.

BREAST (2022)

Meeting Abstract Oncology

First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer

Andrea Vethencourt, Eva M. Trinidad, Anna Petit, Maria T. Soler-Monso, Clara Gomez Aleza, Ander Urruticochea, Amparo Garcia-Tejedor, Anna Guma Martinez, Veronica Obadia, Silvia Vazquez, Rafael Villanueva, Adela Fernanez, Monica Cejuela, Sabela Recalde Penabad, Agostina Stradella, Miguel Gil-Gil, Sonia Pernas, Eva Gonzalez-Suarez, Catalina Falo

CANCER RESEARCH (2022)

Article Oncology

Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research

Renee van Amerongen, Mohamed Bentires-Alj, Antonius L. L. van Boxtel, Robert B. B. Clarke, Silvia Fre, Eva Gonzalez Suarez, Richard Iggo, Martin Jechlinger, Jos Jonkers, Marja L. Mikkola, Zuzana Sumbalova Koledova, Therese Sorlie, Maria dM. Vivanco

Summary: On December 8, 2022, the ENBDC's organizing committee organized its fifth annual Think Tank meeting in Amsterdam, the Netherlands. The meeting aimed to review the most important breakthroughs of the past ten years and discuss the challenges that lie ahead in the field of mammary gland biology and breast cancer research. The outcomes of the discussions are presented in this position paper, with the hope of providing a summary for early career researchers and inspiring scientists and clinicians to advance the field.

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2023)

Article Multidisciplinary Sciences

Luminal Rank loss decreases cell fitness leading to basal cell bipotency in parous mammary glands

Ana Sofia Rocha, Alejandro Collado-Sole, Osvaldo Grana-Castro, Jaime Redondo-Pedraza, Gonzalo Soria-Alcaide, Alex Cordero, Patricia G. Santamaria, Eva Gonzalez-Suarez

Summary: The Rank signaling pathway plays a crucial role in mammary gland homeostasis and epithelial cell differentiation. Loss of luminal Rank leads to abnormal alveolar differentiation and lactation failure, which can be restored by activating bipotency in basal cells during subsequent pregnancies.

NATURE COMMUNICATIONS (2023)

Article Oncology

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

Adrian Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galvan, Sandra Benitez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, Maria Teresa Soler-Monso, Gemma Vinas, Mansour Alsaleem, Emad A. Rakha, Andrew R. Green, Patricia G. Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, Aleix Prat, Teresa Puig, Eva Gonzalez-Suarez

Summary: The study found that RANK and RANKL proteins are more frequently detected in HER2-positive tumors that have acquired resistance to anti-HER2 therapies. After neoadjuvant therapy, RANK gene expression increased, and overactivation of the RANK signaling pathway enhanced ERK and NF-kappa B signaling, leading to increased resistance to lapatinib.

BREAST CANCER RESEARCH (2021)

No Data Available